Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 327 Neoplasm Metastasis 40 Neoplasms 25 Advanced Breast Cancer 19 Ovarian Neoplasms 18 Carcinoma, Non-Small-Cell Lung 14 Endometrial Neoplasms 11 Prostatic Neoplasms 10 Hereditary Sensory and Autonomic Neuropathies 10 Triple Negative Breast Neoplasms 8 Colorectal Neoplasms 6 Breast Cancer Metastatic 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Recurrence 5 Multiple Endocrine Neoplasia Type 1 5 Carcinoma, Ovarian Epithelial 5 Breast Diseases 5 Neoplasms by Site 4 Stomach Neoplasms 3 Small Cell Lung Carcinoma 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma, Lobular 3 Breast Neoplasm Female 3 Uterine Neoplasms 2 Pancreatic Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Fulvestrant 1 Epirubicin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Fulvestrant × Clear all

NCT06998407 2026-05-04

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡